Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$22.19 USD
+0.21 (0.96%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $22.21 +0.02 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CLDX 22.19 +0.21(0.96%)
Will CLDX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CLDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLDX
scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
CLDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates
Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?
Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates
Other News for CLDX
Interesting CLDX Put And Call Options For September 19th
RBC downgrades Jasper Therapeutics on questions about briquilimab
Celldex Therapeutics’ Promising Phase 2 Study on Eosinophilic Esophagitis
Celldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Urticaria
Celldex Therapeutics Advances Phase 2 Study on Barzolvolimab for Prurigo Nodularis